In a rat model of trinitrobenzenesulfonic acid-induced colitis, treatment with mesalazine, a therapy for ulcerative colitis (UC), increased the ratio of CD8+CD28+/CD8+CD28− T cells in the blood. Here, CD28 is linked to ulcerative colitis.